US Stock MarketDetailed Quotes
QNCX Quince Therapeutics
- 1.960
- -0.120-5.77%
Close Nov 22 16:00 ET
- 1.910
- -0.050-2.55%
Post 20:01 ET
86.24MMarket Cap-1580P/E (TTM)
2.450High1.680Low1.05MVolume2.230Open2.080Pre Close2.22MTurnover2.98%Turnover RatioLossP/E (Static)44.00MShares2.45052wk High1.92P/B69.24MFloat Cap0.51252wk Low--Dividend TTM35.33MShs Float121.980Historical High--Div YieldTTM37.02%Amplitude0.512Historical Low2.112Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Quince Therapeutics Stock Forum
No reverse split! Moving up🙏🏻lookinh forward to next week!
📊⚡️📊
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics (Nasdaq: QNCX) announced the publication of Phase 3 ATTeST clinical trial data in The Lancet Neurology, evaluating EryDex for treating Ataxia-Telangiectasia (A-T). The study, involving 175 participants across 22 institutions in 12 countries, demonstrated a favorable safety pro...
No comment yet